36 results
424B5
NLSP
NLS Pharmaceutics Ltd
22 Mar 24
Prospectus supplement for primary offering
10:24am
not give rise to any commitment by the placement agent to purchase any of the securities, and the placement agent will have no authority to bind us … prospective offering. The placement agent has no commitment to buy any of the securities offered pursuant to this prospectus supplement and accompanying
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
29 Dec 23
Report of Foreign Private Issuer
4:30pm
for their hard work and commitment to delivering value every day. And to our shareholders, investors and partners, your ongoing trust and support help us … make NLS the best it can be, every day. Thank you for the trust you place in and shared commitment to NLS Pharmaceutics.
I wish all our stakeholders
6-K
EX-99.2
NLSP
NLS Pharmaceutics Ltd
6 Dec 23
Unaudited Interim Condensed Financial Statements
4:44pm
in October 2021, following the execution date of the SEDA.
We have also agreed to pay YA, or its affiliates, a commitment fee, or the Commitment Fee … , equal to $400,000, or 2% of the aggregate amount available to be sold under the SEDA. We paid half of the Commitment Fee on the execution date
6-K
EX-99.2
NLSP
NLS Pharmaceutics Ltd
16 Nov 23
Report of Foreign Private Issuer
4:05pm
.
In response to the ever-evolving biotech and pharmaceutical landscape and driven by a commitment to innovation, NLS has initiated a comprehensive
6-K
EX-99.1
NLSP
NLS Pharmaceutics Ltd
30 Aug 23
Report of Foreign Private Issuer
5:25pm
, for your continued support for and shared commitment to NLS.
With gratitude,
Alex Zwyer
Chief Executive Officer
Safe Harbor Statement
This press
6-K
EX-99.1
kq2o6 mj3
2 May 23
Report of Foreign Private Issuer
8:30am
6-K
EX-99.1
tfr9ga5 cjk
22 Dec 22
NLS Pharmaceutics CEO Issues Letter to Shareholders
9:40am
F-3
vd5m b7i5z2ai89u
6 Dec 22
Shelf registration (foreign)
4:41pm
6-K
EX-99.1
1pvglbmk
1 Dec 22
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
8:00am
6-K
EX-99.1
vr8tz
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
6-K
EX-99.2
t02zwp
11 Oct 22
Unaudited Interim Condensed Financial Statements
5:20pm
F-1
qct29c2i59cjw4oij
10 Jun 22
Registration statement (foreign)
4:43pm
6-K
EX-10.2
s0zpev7lgdvd mn
14 Apr 22
NLS Pharmaceutics Ltd. Announces US$4.4 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
4:58pm
424B5
dqajpskpf1h
14 Apr 22
Prospectus supplement for primary offering
4:48pm
6-K
EX-1.1
q9gx 64j4wsyz0try4x
4 Mar 22
Report of Foreign Private Issuer
4:02pm
424B5
mipbejfjd
4 Mar 22
Prospectus supplement for primary offering
4:01pm
F-3
zvgyjrog kx
3 Feb 22
Shelf registration (foreign)
4:00pm
F-1
9aam76kzk uggve8b
20 Dec 21
Registration statement (foreign)
4:06pm